CAGRISEMA

Summary

CagriSema is a fixed combination of the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide developed as an injectable anti-obesity therapy. In the phase III REDEFINE 1 trial of adults with overweight or obesity it reduced blood pressure ^[1], and a systematic review and meta-analysis found CagriSema outperformed semaglutide for weight loss, with cagrilintide alone showing weight loss comparable to semaglutide or liraglutide ^[2]. A network meta-analysis of GLP-1 receptor agonists provides broader comparative context for this drug class on glycemic control, weight, and lipids ^[3]. Mechanistic work in rats indicates roughly one-third of CagriSema's weight-loss efficacy arises from preserved energy expenditure and blunted metabolic adaptation rather than reduced food intake alone ^[4]. The key caveat is tolerability: gastrointestinal adverse events and vomiting were significantly higher with CagriSema than with semaglutide ^[2], and it remains investigational rather than approved.

Sources

1. 1. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension (Dallas, Tex. : 1979), 2026.
2. 2. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis Indian journal of endocrinology and metabolism, 2024.
3. 3. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis BMJ (Clinical research ed.), 2024.
4. 4. CagriSema drives weight loss in rats by reducing energy intake and preserving energy expenditure Nature metabolism, 2025.

For educational purposes only.